(CROX) Crocs - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US2270461096
Stock: Clogs, Sandals, Sneakers, Slides, Boots
Total Rating 29
Risk 94
Buy Signal -1.11
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 45.4% |
| Relative Tail Risk | -16.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.05 |
| Alpha | -29.56 |
| Character TTM | |
|---|---|
| Beta | 1.153 |
| Beta Downside | 0.483 |
| Drawdowns 3y | |
|---|---|
| Max DD | 54.04% |
| CAGR/Max DD | -0.20 |
Description: CROX Crocs January 09, 2026
Crocs, Inc. (NASDAQ:CROX) designs, manufactures, and markets a broad portfolio of casual footwear and accessories-including clogs, sandals, sneakers, and related items-under the Crocs and HEYDUDE brands. The company reaches consumers through a mix of wholesale partners, company-owned retail stores, e-commerce sites, third-party marketplaces, and kiosk or store-in-store concepts, operating globally from its headquarters in Broomfield, Colorado.
Recent financials (Q3 2024, subject to revision) show CROX generating roughly $2.5 billion in annual revenue with a gross margin around 45%, while direct-to-consumer (DTC) sales have accelerated at an estimated 20 % year-over-year rate-reflecting the broader footwear sector’s shift toward online channels. Inventory turnover has improved to approximately 3.2×, indicating better demand forecasting, and the company’s exposure to discretionary consumer spending makes it sensitive to macro-level factors such as household income trends and inflation-adjusted price elasticity.
For a deeper quantitative assessment of CROX’s valuation relative to peers, the ValueRay platform offers a concise, data-driven dashboard worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 182.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA -3.29 > 1.0 |
| NWC/Revenue: 6.86% < 20% (prev 7.31%; Δ -0.45% < -1%) |
| CFO/TA 0.18 > 3% & CFO 779.8m > Net Income 182.5m |
| Net Debt (1.55b) to EBITDA (378.2m): 4.10 < 3 |
| Current Ratio: 1.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.2m) vs 12m ago -7.28% < -2% |
| Gross Margin: 59.08% > 18% (prev 0.58%; Δ 5850 % > 0.5%) |
| Asset Turnover: 90.38% > 50% (prev 86.41%; Δ 3.97% > 0%) |
| Interest Coverage Ratio: 1.67 > 6 (EBITDA TTM 378.2m / Interest Expense TTM 180.9m) |
Altman Z'' 4.63
| A: 0.06 (Total Current Assets 971.2m - Total Current Liabilities 691.7m) / Total Assets 4.30b |
| B: 0.79 (Retained Earnings 3.38b / Total Assets 4.30b) |
| C: 0.07 (EBIT TTM 301.9m / Avg Total Assets 4.51b) |
| D: 1.14 (Book Value of Equity 3.33b / Total Liabilities 2.94b) |
| Altman-Z'' Score: 4.63 = AA |
Beneish M -3.27
| DSRI: 0.93 (Receivables 359.0m/386.2m, Revenue 4.07b/4.07b) |
| GMI: 0.98 (GM 59.08% / 58.15%) |
| AQI: 0.95 (AQ_t 0.64 / AQ_t-1 0.67) |
| SGI: 1.00 (Revenue 4.07b / 4.07b) |
| TATA: -0.14 (NI 182.5m - CFO 779.8m) / TA 4.30b) |
| Beneish M-Score: -3.27 (Cap -4..+1) = AA |
What is the price of CROX shares?
As of February 10, 2026, the stock is trading at USD 84.09 with a total of 1,355,860 shares traded.
Over the past week, the price has changed by -3.21%, over one month by -2.30%, over three months by +13.50% and over the past year by -7.35%.
Over the past week, the price has changed by -3.21%, over one month by -2.30%, over three months by +13.50% and over the past year by -7.35%.
Is CROX a buy, sell or hold?
Crocs has received a consensus analysts rating of 4.20.
Therefore, it is recommended to buy CROX.
- StrongBuy: 7
- Buy: 4
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CROX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 89.8 | 6.7% |
| Analysts Target Price | 89.8 | 6.7% |
| ValueRay Target Price | 83.2 | -1% |
CROX Fundamental Data Overview February 03, 2026
P/E Trailing = 28.6416
P/E Forward = 7.4963
P/S = 1.1254
P/B = 3.1424
P/EG = -31.83
Revenue TTM = 4.07b USD
EBIT TTM = 301.9m USD
EBITDA TTM = 378.2m USD
Long Term Debt = 1.32b USD (from longTermDebt, last quarter)
Short Term Debt = 84.3m USD (from shortTermDebt, last quarter)
Debt = 1.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.55b USD (from netDebt column, last quarter)
Enterprise Value = 6.14b USD (4.58b + Debt 1.71b - CCE 154.0m)
Interest Coverage Ratio = 1.67 (Ebit TTM 301.9m / Interest Expense TTM 180.9m)
EV/FCF = 8.57x (Enterprise Value 6.14b / FCF TTM 716.2m)
FCF Yield = 11.67% (FCF TTM 716.2m / Enterprise Value 6.14b)
FCF Margin = 17.59% (FCF TTM 716.2m / Revenue TTM 4.07b)
Net Margin = 4.48% (Net Income TTM 182.5m / Revenue TTM 4.07b)
Gross Margin = 59.08% ((Revenue TTM 4.07b - Cost of Revenue TTM 1.67b) / Revenue TTM)
Gross Margin QoQ = 58.52% (prev 61.67%)
Tobins Q-Ratio = 1.43 (Enterprise Value 6.14b / Total Assets 4.30b)
Interest Expense / Debt = 6.58% (Interest Expense 112.3m / Debt 1.71b)
Taxrate = 23.02% (43.6m / 189.4m)
NOPAT = 232.4m (EBIT 301.9m * (1 - 23.02%))
Current Ratio = 1.40 (Total Current Assets 971.2m / Total Current Liabilities 691.7m)
Debt / Equity = 1.25 (Debt 1.71b / totalStockholderEquity, last quarter 1.36b)
Debt / EBITDA = 4.10 (Net Debt 1.55b / EBITDA 378.2m)
Debt / FCF = 2.17 (Net Debt 1.55b / FCF TTM 716.2m)
Total Stockholder Equity = 1.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.05% (Net Income 182.5m / Total Assets 4.30b)
RoE = 11.08% (Net Income TTM 182.5m / Total Stockholder Equity 1.65b)
RoCE = 10.18% (EBIT 301.9m / Capital Employed (Equity 1.65b + L.T.Debt 1.32b))
RoIC = 7.67% (NOPAT 232.4m / Invested Capital 3.03b)
WACC = 8.79% (E(4.58b)/V(6.29b) * Re(10.17%) + D(1.71b)/V(6.29b) * Rd(6.58%) * (1-Tc(0.23)))
Discount Rate = 10.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.88%
[DCF Debug] Terminal Value 77.12% ; FCFF base≈805.8m ; Y1≈910.3m ; Y5≈1.23b
Fair Price DCF = 322.7 (EV 18.30b - Net Debt 1.55b = Equity 16.75b / Shares 51.9m; r=8.79% [WACC]; 5y FCF grow 15.10% → 2.90% )
EPS Correlation: -25.64 | EPS CAGR: -42.31% | SUE: -4.0 | # QB: 0
Revenue Correlation: 64.43 | Revenue CAGR: 15.17% | SUE: 1.95 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.53 | Chg30d=+0.012 | Revisions Net=-1 | Analysts=9
EPS next Year (2026-12-31): EPS=11.95 | Chg30d=-0.008 | Revisions Net=-2 | Growth EPS=-1.6% | Growth Revenue=-0.5%
P/E Forward = 7.4963
P/S = 1.1254
P/B = 3.1424
P/EG = -31.83
Revenue TTM = 4.07b USD
EBIT TTM = 301.9m USD
EBITDA TTM = 378.2m USD
Long Term Debt = 1.32b USD (from longTermDebt, last quarter)
Short Term Debt = 84.3m USD (from shortTermDebt, last quarter)
Debt = 1.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.55b USD (from netDebt column, last quarter)
Enterprise Value = 6.14b USD (4.58b + Debt 1.71b - CCE 154.0m)
Interest Coverage Ratio = 1.67 (Ebit TTM 301.9m / Interest Expense TTM 180.9m)
EV/FCF = 8.57x (Enterprise Value 6.14b / FCF TTM 716.2m)
FCF Yield = 11.67% (FCF TTM 716.2m / Enterprise Value 6.14b)
FCF Margin = 17.59% (FCF TTM 716.2m / Revenue TTM 4.07b)
Net Margin = 4.48% (Net Income TTM 182.5m / Revenue TTM 4.07b)
Gross Margin = 59.08% ((Revenue TTM 4.07b - Cost of Revenue TTM 1.67b) / Revenue TTM)
Gross Margin QoQ = 58.52% (prev 61.67%)
Tobins Q-Ratio = 1.43 (Enterprise Value 6.14b / Total Assets 4.30b)
Interest Expense / Debt = 6.58% (Interest Expense 112.3m / Debt 1.71b)
Taxrate = 23.02% (43.6m / 189.4m)
NOPAT = 232.4m (EBIT 301.9m * (1 - 23.02%))
Current Ratio = 1.40 (Total Current Assets 971.2m / Total Current Liabilities 691.7m)
Debt / Equity = 1.25 (Debt 1.71b / totalStockholderEquity, last quarter 1.36b)
Debt / EBITDA = 4.10 (Net Debt 1.55b / EBITDA 378.2m)
Debt / FCF = 2.17 (Net Debt 1.55b / FCF TTM 716.2m)
Total Stockholder Equity = 1.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.05% (Net Income 182.5m / Total Assets 4.30b)
RoE = 11.08% (Net Income TTM 182.5m / Total Stockholder Equity 1.65b)
RoCE = 10.18% (EBIT 301.9m / Capital Employed (Equity 1.65b + L.T.Debt 1.32b))
RoIC = 7.67% (NOPAT 232.4m / Invested Capital 3.03b)
WACC = 8.79% (E(4.58b)/V(6.29b) * Re(10.17%) + D(1.71b)/V(6.29b) * Rd(6.58%) * (1-Tc(0.23)))
Discount Rate = 10.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.88%
[DCF Debug] Terminal Value 77.12% ; FCFF base≈805.8m ; Y1≈910.3m ; Y5≈1.23b
Fair Price DCF = 322.7 (EV 18.30b - Net Debt 1.55b = Equity 16.75b / Shares 51.9m; r=8.79% [WACC]; 5y FCF grow 15.10% → 2.90% )
EPS Correlation: -25.64 | EPS CAGR: -42.31% | SUE: -4.0 | # QB: 0
Revenue Correlation: 64.43 | Revenue CAGR: 15.17% | SUE: 1.95 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.53 | Chg30d=+0.012 | Revisions Net=-1 | Analysts=9
EPS next Year (2026-12-31): EPS=11.95 | Chg30d=-0.008 | Revisions Net=-2 | Growth EPS=-1.6% | Growth Revenue=-0.5%